sub:assertion {
  <http://purl.obolibrary.org/obo/DOID_12799> bl:category bl:Disease .
  sub:association rdf:object <http://purl.obolibrary.org/obo/DOID_12799> ;
    rdf:predicate bl:treats ;
    rdf:subject <https://identifiers.org/drugbank:DB01271> ;
    a rdf:Statement ;
    rdfs:label "elaprase is indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age see use in specific populations 8 4 elaprase is a hydrolytic lysosomal glycosaminoglycan gag specific enzyme indicated for patients with hunter syndrome mucopolysaccharidosis ii mps ii elaprase has been shown to improve walking capacity in patients 5 years and older in patients 16 months to 5 years of age no data are available to demonstrate improvement in disease related symptoms or long term clinical outcome however treatment with elaprase has reduced spleen volume similarly to that of adults and children 5 years of age and older the safety and efficacy of elaprase have not been established in pediatric patients less than 16 months of age 1" ;
    bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation ;
    bl:provided_by <https://w3id.org/um/NeuroDKG> ;
    bl:relation nkg:SymptomaticReliefIndication .
  <https://identifiers.org/drugbank:DB01271> bl:category bl:Drug .
}